Zentalis reports 39% ORR, 7.3-month median PFS for azenosertib+paclitaxel in PROC at ASCO

Zentalis Pharmaceuticals, Inc.

Phase 1b MUIR trial: all-comer PROC (n=46), ORR 39.1%, CBR 58.7%, median DOR 5.6 mo, median PFS 7.3 mo.
At 250 mg intermittent dose (n=12): ORR 50.0%, median DOR 9.2 mo, median PFS 5.5 mo, manageable safety.
Cyclin E1-positive (ORR 41.4%) and -negative (ORR 35.7%) patients showed comparable activity.
Grade ≥3 TRAEs: neutropenia 30.4%, anemia 19.6%; one Grade 5 sepsis event previously reported.
Data supports combo expansion; core focus remains azenosertib monotherapy in Cyclin E1+ PROC.

item 7.01 item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001725160-26-000045
form_type: 8-K
ticker: ZNTL
cik: 0001725160
company_name: Zentalis Pharmaceuticals, Inc.
filed_at: 2026-05-21T21:29:34+00:00
discovered_at: 2026-05-21T21:30:00.387059+00:00
generated_at: 2026-05-21T21:33:34.646606+00:00
sec_items: ["7.01", "8.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001725160-26-000045
json_url: https://secwatch.observer/filing/0001725160-26-000045.json
markdown_url: https://secwatch.observer/filing/0001725160-26-000045.md
text_url: https://secwatch.observer/filing/0001725160-26-000045.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1725160/000172516026000045/0001725160-26-000045-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1725160/000172516026000045/zntl-20260521.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Comparable filings

CSR

Centerspace approves $240-245M asset sales; exits Bismarck and Rapid City

CENTERSPACE June 1, 2026, 4:30 PM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

DBX

Dropbox secures $400M revolving credit facility, authorizes $900M share repurchase program

DROPBOX, INC. June 1, 2026, 9:06 AM ET other_material Items 1.01, 2.03, 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

NXTC

NextCure Phase 1 SIM0505 data: 55% ORR in gynecologic cancers; cash into Q1 2027

NextCure, Inc. June 1, 2026, 8:10 AM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

JBIO

Jade Biosciences reports Phase 1 interim data: JADE101 shows ~70% IgA reduction, favorable safety, differentiated PK

Jade Biosciences, Inc. June 1, 2026, 7:55 AM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

VDTA

Vertical Data launches Vertical Edge, a direct-ownership edge data center platform

Vertical Data Inc. June 1, 2026, 4:47 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

AII

American Integrity fully places 2026-2027 CAT XOL reinsurance with $2.99B total limit

American Integrity Insurance Group, Inc. June 1, 2026, 4:31 PM ET other_material Items 7.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

XAIR

Beyond Air receives Nasdaq panel grant for continued listing; must meet bid price rule by July 31, 2026

Beyond Air, Inc. June 1, 2026, 4:30 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

CTOR

Citius Oncology reports Phase 1 combo data for LYMPHIR in gynecologic cancers; 24% ORR, 33% in endometrial cancer

CITIUS ONCOLOGY, INC. June 1, 2026, 4:30 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

Source: SEC EDGAR

accession 0001725160-26-000045

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.